



## NewTherapiesSubgroup



26<sup>th</sup> July 2011

### Clopidogrel 75mg Tablets

The New Therapies Subgroup discussed the above drug at a meeting on the 26<sup>th</sup> July 2011. The recommendation of this subgroup is as follows:\*

The New Therapies Subgroup of the GMMM considered the therapeutic use of clopidogrel (Plavix<sup>®</sup>) for the prevention of atherothrombotic events post-percutaneous coronary intervention (ACS and STEMI)

**The group recommends that clopidogrel should be used in line with the joint GMCCSN and GMMM joint protocols. (See [here](#) ).**

Please note that the duration of combination treatment for thromboprophylaxis post-PCI should not exceed 12 months. As per the protocols patients will be switched from ticagrelor to clopidogrel 75mg daily (without a loading dose) after 3 months ticagrelor treatment. Clopidogrel will be continued for a further 9 months. Low dose aspirin should be continued thereafter.

As with all prescriptions for clopidogrel - treatment discontinuation dates or duration of treatment must be effectively communicated to patients and their general practitioner.

GM recommendations for the use of clopidogrel in patient with ST segment elevation acute MI is also available.

Prescribers are also reminded that NICE guidance TA210 on the use of clopidogrel for the prevention of occlusive vascular events should be followed.

### **Review Date July 2013**

\* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.